Literature DB >> 11772226

A 1-stage surgical treatment for postherniorrhaphy neuropathic pain: triple neurectomy and proximal end implantation without mobilization of the cord.

Parviz K Amid1.   

Abstract

BACKGROUND: The recommended surgical treatment for chronic neuropathic pain after herniorrhaphy has been a 2-stage operation including: (1) ilioinguinal and iliohypogastric neurectomies through an inguinal approach and (2) genital nerve neurectomy through a flank approach. HYPOTHESIS: A 1-stage surgical procedure resecting all 3 nerves from an anterior approach avoids a second operation through the flank and successfully treats chronic neuralgia.
SETTING: A private practice dedicated to abdominal wall hernia surgery in general community hospitals. PATIENTS: Between 1995 and 2001, 49 patients underwent triple neurectomies with proximal end implantation to treat chronic postherniorrhaphy neuralgia. INTERVENTION: Triple neurectomy of the ilioinguinal, iliohypogastric, and genital nerves performed under local anesthesia with implantation of their proximal ends and without mobilization of the spermatic cord.
RESULTS: Two patients (4%) reported no improvement. Eighty percent of patients recovered completely, and 16% had transient insignificant pain with no functional impairment. These results are comparable to the results of the 2-stage operation.
CONCLUSIONS: Simultaneous neurectomy of the ilioinguinal, iliohypogastric, and genital nerves without mobilization of the spermatic cord is an effective 1-stage procedure to treat postherniorrhaphy neuralgia. It is performed under local anesthesia and avoids testicular complications. Proximal end implantation of the nerves prevents adherence of the cut ends to the aponeurotic structure of the groin, which can result in recurrence of the pain.

Entities:  

Mesh:

Year:  2002        PMID: 11772226     DOI: 10.1001/archsurg.137.1.100

Source DB:  PubMed          Journal:  Arch Surg        ISSN: 0004-0010


  36 in total

1.  Lichtenstein tension-free hernioplasty: its inception, evolution, and principles.

Authors:  Parviz K Amid
Journal:  Hernia       Date:  2003-09-20       Impact factor: 4.739

2.  Use of the LION procedure on the sensitive branches of the lumbar plexus for the treatment of intractable postherniorrhaphy neuropathic inguinodynia.

Authors:  M Possover
Journal:  Hernia       Date:  2011-12-01       Impact factor: 4.739

3.  A single-surgeon randomized trial comparing sutures, N-butyl-2-cyanoacrylate and human fibrin glue for mesh fixation during primary inguinal hernia repair.

Authors:  Mario Testini; Germana Lissidini; Elisabetta Poli; Angela Gurrado; Domenica Lardo; Giuseppe Piccinni
Journal:  Can J Surg       Date:  2010-06       Impact factor: 2.089

4.  Inguinal herniorrhaphy: 25-year results of technical improvements leading to reduced morbidity in 4,029 patients.

Authors:  Maximo Deysine
Journal:  Hernia       Date:  2006-05-19       Impact factor: 4.739

5.  Tension-free plug repair of inguinal hernia.

Authors:  Julian E Losanoff; J Michael Millis
Journal:  World J Surg       Date:  2005-10       Impact factor: 3.352

6.  The outcomes of open tension-free hernioplasty in elderly patients.

Authors:  Marcelo A Beltrán; Karina S Cruces
Journal:  Hernia       Date:  2006-08-17       Impact factor: 4.739

Review 7.  [Intervention-specific complications of hernia surgery].

Authors:  U A Dietz; A Wiegering; C T Germer
Journal:  Chirurg       Date:  2014-02       Impact factor: 0.955

8.  Litigation following groin hernia repair in England.

Authors:  B Alkhaffaf; B Decadt
Journal:  Hernia       Date:  2009-12-11       Impact factor: 4.739

9.  Chronic pain after hernia repair: a randomized trial comparing Shouldice, Lichtenstein and TAPP.

Authors:  Jörg Köninger; Jens Redecke; Michael Butters
Journal:  Langenbecks Arch Surg       Date:  2004-07-09       Impact factor: 3.445

10.  Causes, prevention, and surgical treatment of postherniorrhaphy neuropathic inguinodynia: triple neurectomy with proximal end implantation.

Authors:  P K Amid
Journal:  Hernia       Date:  2004-12       Impact factor: 4.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.